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This prospective, randomized,andcontrolled study examined the eﬀects oftumor necrosis factor solublereceptor type I(sTNFRI,
aT N F - α antagonist) on experimentally induced rhinosinusitis in rats. The experimental groups received an instillation of
lipopolysaccharide (LPS) plus an intramuscular injection of amoxicillin/clavulanate (antibiotic group), an instillation of sTNFRI
(sTNFRIgroup),aninstillationofsTNFRIandaninjectionofamoxicillin/clavulanate(sTNFRI/antibioticgroup),ornoadditional
treatment (LPS group). Histopathological changes were determined using hematoxylin-eosin and periodic acid-Schiﬀ (PAS)
staining. Leakage of exudate was determined using ﬂuorescence microscopy. Vascular permeability was measured using the
Evans blue dye technique. Expression of MUC5AC was measured using reverse transcriptase PCR. The sTNFRI, antibiotic, and
sTNFRI/antibiotic groups had signiﬁcantly less capillary permeability, mucosaledema, PAS staining, and expression of MUC5AC
than the LPS group. There were no diﬀerences in capillary permeability, mucosal edema, PAS staining, and MUC5AC expression
between the sTNFRI and sTNFRI/antibiotic groups. The antibiotic group had PAS staining similar to that of the sTNFRI and
sTNFRI/antibiotic groups but had a greater increase in capillary permeability, mucosal edema, and MUC5AC expression. This
study shows that sTNFRI reduces inﬂammatoryactivity and mucus hypersecretion in LPS-induced rhinosinusitis in rats.
1.Introduction
The respiratory tract is exposed to many external stimuli,
among which are noxious gases, air pollutants, bacteria, and
viruses. Exposure to harmful agents and microbial endotox-
ins can cause airway inﬂammations such as rhinosinusitis,
inﬂammation of the mucosa of the nose and paranasal sinus
[1].Despitethedevelopmentofnewantibioticsandadvances
in sinus surgery over the past few decades, rhinosinusitis
is still an enigmatic process. Moreover, treatment of rhi-
nosinusitis with inappropriate antibiotics has contributed to
the worldwide emergence of antibiotic-resistant strains of
bacteria.
The recent appreciation that exposure to noninfectious
inﬂammatory agents may predispose a person to infectious
rhinosinusitis has stimulated renewed interest in the role
of inﬂammatory mediators and inﬂammatory cells in the
pathogenesis of rhinosinusitis [2, 3]. Many trials have high-
lighted the potential of inﬂammatory mediators for the
treatment of inﬂammatory diseases, including rhinosinusitis
[4–8].
Tumornecrosisfactor(TNF)isanimportant mediatorof
inﬂammation and is produced by macrophages in response
to stimuli such as bacterial lipopolysaccharide (LPS) and
viruses[9].It hasbeendemonstrated that TNF-αantagonists
block the activity of TNF and inhibit its action in vivo [6–
8]. However, few studies have been conducted on the role
of TNF-α antagonists in the treatment and prevention of
rhinosinusitis. Therefore, this study examined the eﬀects
of a TNF-α antagonist on the LPS-induced inﬂammatory
response in the nasal cavity and sinus of rats.2 Journal of Biomedicine and Biotechnology
Table 1: Histopathologicalchanges in nasal mucosa (mean ± SD).
Absorbance Mucosal thickness (mm) PAS-stained area (%)
Group
1st day 4th day 1st day 4th day 1st day 4th day
Saline 0.09 ± 0.04 0.10 ± 0.02 1.01 ± 0.26 1.21 ± 0.67 16.54 ± 1.93 16.39 ± 1.34
LPS 0.17 ± 0.03 0.21 ± 0.01 2.11 ± 1.27 2.26 ± 1.27 22.24 ± 2.90 24.78 ± 3.61
LPS + sTNFRI 0.12 ± 0.01 0.12 ± 0.02 1.32 ± 0.66 1.22 ± 0.45 15.81 ± 1.64 16.24 ± 3.75
LPS + antibiotic 0.12 ± 0.01 0.19 ± 0.01 1.52 ± 0.79 1.97 ± 0.93 14.60 ± 2.75 16.82 ± 1.06
LPS + sTNFRI + antibiotic 0.11 ± 0.02 0.11 ± 0.01 1.17 ± 0.79 1.31 ± 0.57 16.39 ± 1.34 16.31 ± 4.81
Table 2: Signiﬁcance of diﬀerences (P value) in histopathologicalvariables according to the time of sacriﬁce.
Absorbance Mucosal thickness (mm) PAS-stained area (%)
1st day versus 4th day 1st day versus 4th day 1st day versus 4th day
Saline 0.467 0.427 0.196
LPS 0.333 0.803 0.099
LPS + sTNFRI 0.617 0.644 0.149
LPS + antibiotic 0.001∗ 0.189 0.863
LPS + sTNFRI + antibiotic 0.982 0.626 0.980
∗Signiﬁcant (P<. 05).
2.Materialsand Methods
2.1. Materials. The LPS used in this study was derived
from Pseudomonasaeruginosa (L-4524,Sigma, St.Louis, Mo,
USA).It was dissolved in normal saline solution at a concen-
tration of 1mg/mL. TNF soluble receptor type I (sTNFRI)
(PHR3015, Invitrogen, Camarillo, Calif, USA), a TNF-α
antagonist was dissolved in a phosphate-buﬀered saline
(0.1M, pH 7.4) solution at a concentration of 0.2mg/mL.
Sixty-three healthy Sprague Dawley rats, weighing 200–
250g and free of pathogens and respiratory diseases accord-
ing to the health and pathology reports of the supplier,
were used in this study. All animals were housed and
treated according to the regulations of the Catholic Ethics
Committee of the Catholic University of Korea, which
conformed to the NIH guidelines for the use of animals in
research.
2.2. Methods. All experiments were performed with the rats
subjected to 2% xylazine (8mg/kg) anesthesia. Inhalant
anesthesia was avoided to prevent irritation of the nasal
mucosa. Both airways of the nasal cavity received an
instillation of 0.1mL of saline containing 0.1mg LPS once
p e rd a yf o r3 d a y s .T h ei n s t i l l a t ew a sd e p o s i t e da sab e a d
of ﬂuid on the external nares, and the rats were allowed to
aspirate it. Some rats were instilled with saline as a control.
We carefully monitored breathing rate and skin color during
instillation to prevent respiratory failure.
Sixty-three rats were allocated randomly to four treat-
ment groups of 12 animals, each with 15 animals allocated
to the control groups. One control group received no LPS
or saline instillation (normal group; three animals), and the
other control group was instilled with 0.1mL of normal
saline once per day for 3d (saline group; 12 animals).
All experimental groups received an instillation of LPS
(0.1mL) once per day for 3d. The LPS group received
an LPS instillation alone, the sTNFRI group received an
instillation of 0.1mL of an sTNFRI solution, the antibiotic
group received an intramuscular injection of 50mg/kg
amoxicillin/clavulanate, and the sTNFRI/antibiotic group
received an intramuscular injection of 50mg/kg amoxi-
cillin/clavulanate and an instillation of 0.1mL of an sTNFRI
solution.
Each group except the normal group was subclassiﬁed
into two subgroups based on the time of sacriﬁce (on the
1st or 4th days after the ﬁnal instillation of saline or LPS).
Evans blue dye (E2129-10G, Sigma) was injected into the
femoral vein at 20mg/mL per kilogram of body weight 30–
60min before death. The rats turned blue immediately after
infusion of the dye, conﬁrming its uptake and distribution
throughout the body.
The rats were exsanguinated 30min after injection of
dye and residual blood cells were ﬂushed from the vascular
system by perfusion of 100mL of normal saline solution
through an intra-aortic catheter. The nasal cavity was then
lavaged with 0.1mL of formamide for 5min to collect the
extravasated Evans blue dye.
After collecting the extravasated Evans blue dye, the
head was removed and cleaned of skin and fur. A coronal
incision was then made 1mm posterior to the eyes to
extract the maxilla (including the sinonasal cavity) for tissue
processing. Half of the harvested bone was used for reverse
transcriptase PCRanalysis and halfwas usedfor staining.For
staining, the bone was ﬁxed in 10% paraformaldehyde for
24h, decalciﬁed in a rapid decalcifying solution (CalciClear
Rapid, National Diagnostics, Atlanta, Ga, USA), embedded
in a paraﬃn block, and cut into 4-5μm thick sections
perpendicular to the plane of the hard palate. The mucosa
of the maxillary sinus and nasal cavity was stained with
periodic acid-Schiﬀ (PAS) reagent and hematoxylin-eosin to
determine histopathological changes.
2.3. Interpretation. T h ed e g r e ea n dl o c a t i o no ft h eE v a n s
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Table 3: Signiﬁcance of diﬀerences (P value) in histopathologicalvariables between the LPS and other groups.
Absorbance Mucosal thickness (mm) PAS-stained area (%)
1st day 4th day 1st day 4th day 1st day 4th day
LPS versus saline 0.033∗ 0.031∗ 0.064 0.019∗ 0.001∗ 0.001∗
LPS versus LPS + sTNFRI 0.001∗ 0.049∗ 0.171 0.011∗ 0.001∗ 0.001∗
LPS versus LPS + antibiotic 0.002∗ 0.603 0.299 0.461 0.001∗ 0.006∗
LPS versus LPS + sTNFRI + antibiotic 0.001∗ 0.046∗ 0.116 0.014∗ 0.001∗ 0.008∗
∗Signiﬁcant (P<. 05).
Table 4: Signiﬁcanceof diﬀerences (P value) in histopathological variables between treatments.
Absorbance Mucosal thickness (mm) PAS-stained area (%)
1st day 4th day 1st day 4th day 1st day 4th day
sTNFRI versus antibiotic 0.191 0.001∗ 0.519 0.008∗ 0.287 0.819
Antibiotic versus sTNFRI + antibiotic 0.096 0.001∗ 0.305 0.022∗ 0.197 0.873
sTNFRI versus sTNFRI + antibiotic 0.489 0.743 0.624 0.659 0.528 0.987
∗Signiﬁcant (P<. 05).
mucosa were examined on unstained slides using confocal
scanning microscopy (543nm, Bio-Rad Radiance Plus, Bio-
Rad, Hemel Hempstead, UK). To quantify the amount of
extravasated dye, absorbance of the supernatant at 630nm
wasmeasured usingaspectrophotometer(Du-530,Beckman
Coulter, Fullerton, Calif, USA).
The thickness of the mucosa was deﬁned as the maxi-
mum thickness of the mucosa overlying the maxillary sinus
and was measured at a magniﬁcation of ×400. The mean
mucosal thickness was calculated using three sections per
group.
MetaMorph imaging software (Molecular Devices Inc.,
Downing Town, Pa, USA) was used to evaluate the area of
PAS staining [10–12] in the mucosa of the nasal opening
at the base of the nasal septum. The total area of mucosa
of the nasal opening at the base of the nasal septum was
also measured, and the PAS-stained area was expressed as a
percentage of the total area. Image analysis was performed
using a blinded protocol.
The other half of the harvested bone was homogenized,
frozeninliquidnitrogen,andstoredat−70◦C.RNAwasthen
extracted using an extraction kit (iNtRON Biotechnology,
Inc., Gyeonggi-do, Korea) according to the manufacturer’s
instructions.
Polymerase activation for MUC5AC was performed at
95◦Cfor15minfollowedby32cyclesat94◦Cfor1min,55 ◦C
for 1min, and 72◦C for 1min. Polymerase activation for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
performed at 94◦C for 4min, followed by 35 cycles at 94◦C
for 1min, 60◦Cf o r1m i n ,a n d7 2 ◦Cf o r1m i n .
The primer sequences were obtained from GenBank
and were designed using Gene Runner software (Hastings
Software Inc., Las Vegas, Nev, USA). The sequences of the
primers were as follows: MUC5AC: forward, 5 -CATAGC-
CTCCTCTTGTTC-3  and reverse, 3 -ATTCCTGTAGCA-
GTAGTGAG-5 ;a n dG A P D H :f o r w a r d ,5  -GCTGGTGCT-
GAGTATGTCGT-3  and reverse, 3 -GAATGGGAGTTG-
CTGTTGAA-5 . GAPDH was used as a constitutive control.
The products were separated by agarose gel electrophoresis
and visualized using ethidium bromide staining. The bands
were digitized using a Bio-Rad Universal Hood system (Bio-
Rad, Hercules, Calif, USA). The mean MUC5AC to GAPDH
band photodensity ratio was calculated for each group.
2.4. Statistics. Group means were compared using the
Kruskal-Wallis test and SAS version 8.1 software (SAS
institute, Inc., Cary, NC, USA). The results are presented
as the mean ± standard deviation. A P value < .05 was
considered signiﬁcant.
3.Resultsand Discussion
3.1. Changes in the Microvascular Permeability of the Mucosa
of the Nasal Cavity and Sinus. The mean absorbance of the
LPS group increased with time, but the increase was not
signiﬁcant. The mean absorbances of all other groups except
the antibiotic group showed no signiﬁcant changes with
time. The antibiotic group showed a signiﬁcant increase in
absorbancewith time(Tables1and2).Themeanabsorbance
of the LPS group was signiﬁcantly greater than that of the
saline group on the 1st and 4th days (Tables 1 and 3).
The mean absorbances of the LPS group were compared
with those of the sTNFRI, antibiotic, and sTNFRI/antibiotic
groups.Althoughtherewasnosigniﬁcant diﬀerencebetween
the LPS group and the antibiotic group on the 4th day,
the mean absorbances of the other study groups were
signiﬁcantly less than those of the LPS groups (Tables 1 and
3).
Mean absorbances were compared between the sTNFRI,
antibiotic, and sTNFRI/antibiotic groups. There was no sig-
niﬁcant diﬀerence in absorbance between groups except for
that of the antibiotic subgroup that was sacriﬁced on the 4th
day, which was signiﬁcantly greater than those of thesTNFRI
and sTNFRI/antibiotic groups on the 4th day (Tables 1 and
4).4 Journal of Biomedicine and Biotechnology
(a) (b) (c)
(d) (e) (f)
Figure 1: Fluorescence microscope images of Evans blue dye leakage on the 4th day. (a) Normal group; (b) saline group; (c) LPS group; (d)
sTNFRI group; (e) antibiotic group; (f) sTNFRI/antibiotic group. Massive leakage of Evans blue dye was observed in the mucosa of the LPS
group ((c), arrows) (×400).
Little Evans blue dye was extravasated in the saline,
sTNFRI,antibiotic,and sTNFRI/antibioticgroups. However,
E v a n sb l u ed y ew a se x t r a v a s a t e di n t ot h em u c o s ai nt h eL P S
group (Figure 1).
3.2. Thickness of the Maxillary Sinus Mucosa. There were no
signiﬁcant diﬀerences in mucosal thickness between the 1st
day and the 4th day. The mean mucosal thickness of the
LPS group, antibiotic group, and sTNFRI/antibiotic group
increased with time, whereas the mean mucosal thickness of
thesTNFRIgrouptendedtodecreasewithtime(Tables1and
2).
Compared with the saline group, the mean mucosal
thickness of the LPS group increased signiﬁcantly on the 4th
day (Tables 1 and 3). The mean mucosal thicknessof the LPS
group was compared with those of the sTNFRI, antibiotic,
and sTNFRI/antibiotic groups. Although the mean mucosal
thickness of the sTNFRI, antibiotic, and sTNFRI/antibiotic
groups was less than that of the LPS group on the 1st
day, there was no signiﬁcant diﬀerence between each group
and the LPS group on the 1st day. The mean mucosal
thicknesses of the sTNFRI and sTNFRI/antibiotic groups
were signiﬁcantly less than that of the LPS group on the
4th day (Figure 2). Although the mean mucosal thickness
of the antibiotic group appeared to be less than that of the
LPS group on the 4th day, the diﬀerence was not statistically
signiﬁcant (Tables 1 and 3).
Mean mucosal thickness was compared between the
sTNFRI, antibiotic, and sTNFRI/antibiotic groups. There
were no signiﬁcant diﬀerences between the three groups
o nt h e1 s td a y .H o w e v e r ,t h e r ew e r es i g n i ﬁ c a n td i ﬀerences
between the sTNFRI and antibiotic groups, as well as
between the antibiotic and sTNFRI/antibiotic groups, on
the 4th day. There was no signiﬁcant diﬀerence between the
sTNFRIandsTNFRI/antibioticgroupsonthe4thday(Tables
1 and 4).
3.3. Morphometry. The mean area of PAS staining of the
LPS group increased with time, but the increase was not
signiﬁcant. The mean areas of PAS staining of the other
groups did not change signiﬁcantly with time (Tables 1 and
2).
Compared with the saline group, the PAS-stained areas
of the LPS group were signiﬁcantly elevated on the 1st and
4th days (Tables 1 and 3). The mean areas of PAS staining of
the LPS groups were compared with those of the sTNFRI,
antibiotic, and sTNFRI/antibiotic groups (Figure 3). The
mean areas of PAS staining of all study groups were
signiﬁcantly lower than those of the LPS groups on the 1st
and4thdays(Tables1and3).ThemeanareasofPASstainingJournal of Biomedicine and Biotechnology 5
(a) (b) (c)
(d) (e) (f)
Figure 2: Photomicrographs of sinus mucosa on the 4th day. The mucosa was thin in the normal (a) and saline (b) control groups. In the
LPS group (c), the mucosa was markedly thickened. The sTNFRI (d), antibiotic (e), and sTNFRI/antibiotic (f) groups showed signiﬁcant
decreases in mucosalthickening compared with the LPS group (c) (hematoxylin-eosinstaining; scale bar = 1mm).
of the sTNFRI, antibiotic, and sTNFRI/antibiotic groups
were similar on the 1st and 4th days (Tables 1 and 4).
3.4. MUC5AC Expression in the Nasal Cavity and Sinus.
Compared with the saline control group, LPS induced a
10.5-fold increase in mucin gene expression on the 1st day
(Figure 4) and a 6.5-fold increase in mucin gene expression
on the 4th day (Figure 5). Upregulation of MUC5AC mRNA
expression was signiﬁcantly inhibited in the sTNFRI, antibi-
otic, and sTNFRI/antibiotic groups. The level of MUC5AC
mRNA expression in the antibiotic group was signiﬁcantly
higher than that in the sTNFRI and sTNFRI/antibiotic
groups on the 1st and 4th days (P = .001).
This studyexaminedinﬂammatory responses inratswith
LPS-induced rhinosinusitis. LPS was used as an infectious
agent instead of a bacterium. Streptococcus pneumoniae,
Haemophilus inﬂuenza,a n dMoraxella catarrhalis are cited
as the most common bacterial pathogens responsible for
acutesinusitis [13].Gram-negative bacteriasuchasKlebsiella
pneumoniae, Pseudomonas aeruginosa, Serratia marcescens,
and Proteus mirabilis are reported to cause sinusitis infre-
quently, mainly in immunocompromised patients [14].
Recent investigations indicated that Gram-negative bacteria
are frequently involved in sinusitis that is recalcitrant to
traditional medical and surgical therapy, even in immuno-
competent patients [15, 16]. LPS is the primary component
of endotoxin, a mixture of Gram-negative bacteria cell wall
components [17]. Endotoxin is not readily eradicated by
the local host defense mechanism and has been shown to
persist for up to three months, even after eﬀective antibiotic
treatment [6, 18].
In the present study, capillary permeability, mucosal
edema, PAS staining, and expression of MUC5AC were
examined on the 1st and 4th days after the ﬁnal instillation
of LPS. The percentage area stained by PAS, which indicates
the production of mucosubstance and the mRNA expression
of MUC5AC, a major mucin secreted from the goblet cells
of the surface epithelium and the most important mucin
in the pathogenesis of mucus hypersecretion [19–21], were
analyzed to evaluate mucus hypersecretion.6 Journal of Biomedicine and Biotechnology
(a) (b) (c)
(d) (e) (f)
Figure 3: Histopathological images of nose-tissue sections stained with PAS on the 4th day. (a) Normal group; (b) saline group; (c) LPS
group; (d) sTNFRI group; (e) antibiotic group; (f) sTNFRI/antibiotic group. A large PAS-stained area was observed in the LPS group ((c),
arrow), and luminal inﬂammatorycell clumping was noted in the antibiotic group ((e), arrow) (×200).
Compared with intranasal saline instillation, intranasal
LPS instillation signiﬁcantly increased microvascular perme-
ability, mucosal thickness, and the percentage of PAS-stained
area and induced overexpression of MUC5AC on the 1st
and 4th days. Inﬂammation and mucus hypersecretion of
thesinonasal tract were observedafterLPSinstillation. These
ﬁndings are similar to the characteristics of the rat model of
platelet activating factor-induced rhinosinusitis [22].
Although the mean absorbance, mucosal thickness, and
PAS-stained area of the LPS groups increased with time,
the increases were not signiﬁcant. LPS induced a 10.5-fold
increase in mucin gene expression compared with the saline
controlgroup on the1st day and a 6.5-fold increase in mucin
gene expression on the 4th day.
We did not document the time course of inﬂammation
in this study. Liu et al. reported that the threshold time point
for inducible nitric oxide synthase mRNA induction was
between 20min and 40min after LPS administration, and
thatthequantityofmRNAincreased progressively thereafter,
reaching a plateau between 4h and 8h, and decreasing
markedly by 24h in rats treated with LPS [23]. We consider
the time course reported by Liu et al. applicable to our study.
Further studies are required to determine the exact time
course of inﬂammation after intranasal LPS instillation. To
verify our hypothesis, additional studies on the relationship
between inducible nitric oxide synthase messenger RNA and
LPS-induced rhinosinusitis are needed.
Antibiotics are commonly used to treat bacterial rhinos-
inusitis. Amoxicillin is generally used as a ﬁrst treatment,
and amoxicillin/clavulanate is indicated when the patient’s
symptoms do not improve with amoxicillin alone [17].
Although the LPS-induced expression of MUC5AC and
the increase in PAS staining were signiﬁcantly reduced
by amoxicillin/clavulanate compared with the LPS group,
LPS-induced increases in microvascular permeability and
mucosal thickness were less aﬀected. In addition, LPS-
stimulated expression of MUC5AC was higher in the
antibiotic group than that in the sTNFRI group. The
antibiotic group had greater microvascular permeability,
mucosal thickness, and MUC5AC mRNA expression than
the sTNFRI groups. This diﬀerence was signiﬁcant on the
4th day. These results show that amoxicillin/clavulanate is
less eﬀective in treating LPS-induced rhinosinusitis than
sTNFRI. Because the agent used to induce rhinosinusitis
in this study was not a bacterium but LPS, it appears
that amoxicillin/clavulanate, which acts by inhibiting the
synthesis ofbacterialcellwalls,waslesseﬀectivethansTNFRI
in treating LPS-induced rhinosinusitis. Ou et al. reported
that amoxicillin had no eﬀect on MUC5AC expression
during a pulmonary inﬂammatory response to LPS [24].Journal of Biomedicine and Biotechnology 7
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(b) Optical densityratio of MUC5AC mRNA as assessedby image analysis
Figure 4: Expression of MUC5AC mRNA in the rat nose on the 1st day after the last instillation of LPS. Expression of MUC5AC mRNA
increased signiﬁcantly in rats treated with LPS, and the upregulation of MUC5AC mRNA expression was inhibited by sTNFRI, antibiotic,
and sTNFRI/antibiotic (P<. 05).
Cytokines such as interleukin (IL)-1 beta, IL-8, and
TNF-α are produced by monocytes and play an important
role in the inﬂammatory response to LPS [25–27]. The
proinﬂammatory cytokines, IL-1 beta, and TNF-α stimulate
neutrophils to release oxidants and proteases and stimulate
endothelial cells to produce vascular cell adhesion molecule-
1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-
1), which facilitate the adherence of leukocytes to vascular
endothelial cells. Therefore, leukocytes inﬁltrate the airways
and cause injury by releasing inﬂammatory products [28–
31]. Tumor necrosis factor-soluble receptor (sTNFR) acts as
an inhibitor by binding to TNF-α and preventing its binding
to the cell surface receptor. Hence, it inhibits the activity of
TNF-α. Two typesofsTNFR are recognized: sTNFRI(60kD)
and sTNFRII (80kD). sTNFRI is more potent than sTNFRII
[32]. Lee et al. reported that sTNFRI prevented experimental
otitis media when eﬀusion was induced using TNF-α [6].
Kim et al. demonstrated that sTNFRI prevents experimental
otitis media when eﬀusion is induced using LPS [7].
Based on these reports [6, 7, 25–32], this study examined
thepreventiveeﬀectsofaTNF-αantagonistoninﬂammatory
responses induced by LPS in the nasal cavity and sinus.
intranasal instillation of sTNFRI attenuated LPS-induced
increases in microvascular permeability and PAS staining
in the sinonasal tract on the 1st and 4th days. sTNFRI
reduced LPS-induced increases in mucosal thickness on the
4thday.Inaddition,sTNFRIattenuatedLPS-inducedmRNA
overexpression of MUC5AC on the 1st and 4th days. These
attenuating eﬀects were similar on the 1st and 4th days.
These results suggest that sTNFRI suppresses both inﬂam-
mationandmucushypersecretionbydownregulatingmRNA
expression of MUC5AC. Therefore, intranasal instillation of
sTNFRI eﬀectively prevents LPS-induced rhinosinusitis in
rats.
The sTNFRI/antibiotic combination attenuated LPS-
induced increases in microvascular permeability and PAS
staining on the 1st and 4th days. The sTNFRI/antibiotic
combination reduced LPS-induced increases in mucosal
thickness onthe 4th day and attenuated LPS-induced mRNA
overexpression of MUC5AC on the 1st and 4th days.
Asthe eﬀectsofsTNFRI/antibioticbeargreatersimilarity
to those of the sTNFRI group than those of the antibiotic
group, the eﬀects of the sTNFRI/antibiotic combination are
probably due to the eﬀect of the sTNFRI component rather
than that of the antibiotic component.8 Journal of Biomedicine and Biotechnology
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(b) Optical densityratio of MUC5AC mRNA as assessedby image analysis
Figure 5: Expression of MUC5AC mRNA in the rat nose on the 4th day after the ﬁnal instillation of LPS. The level of MUC5AC mRNA
expression was signiﬁcantly higher in rats treated with LPS, and upregulation of MUC5AC mRNA expression was inhibited by sTNFRI,
antibiotic, and sTNFRI/antibiotic (P<. 05).
Further studies to compare the eﬀects of other inhibitors
(such as a platelet-activating factor antagonist) with those of
sTNFRIareneededtoidentifymorepotentinhibitorsofLPS-
induced rhinosinusitis.
4.Conclusions
Intranasal administration of sTNFRI reduces inﬂammatory
activity, including elevated microvascular permeability and
tissue edema, and mucus hypersecretion, including produc-
tion of mucosubstance and expression of MUC5AC, in LPS-
inducedrhinosinusitis in rats.Theseresults demonstratethat
intranasal administration of sTNFRI reduces inﬂammatory
activity and mucus hypersecretion in LPS-induced rhinosi-
nusitis in rats.
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